Publication | Closed Access

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Transplantation-eligible PatientsHematological MalignancyTransplantationHealth SciencesImmunotherapyMedicineImmunologyHematologyImmune Checkpoint InhibitorMultiple MyelomaRadiation OncologyOncologyCell TransplantationFinal Analysis